Dabur India Reports Resilient Q1 FY26 Performance, Eyes Double-Digit Growth in Q2
The announcement provides detailed quarterly financial performance, category-wise growth, and crucial future guidance on revenue and margins. It also outlines key strategic initiatives, including M&A and focus on core brands, which are significant for long-term company performance and investor decisions.
The company demonstrated resilience with growth in core categories and international business despite challenges. It gained market share across 95% of its portfolio. Management expressed optimism for future growth, aiming for double-digit growth in Q2 FY26 and high single-digit for the full year, backed by strategic initiatives and expected margin improvement.
Dabur India Limited held its Investors' Conference Call on July 31, 2025, following the declaration of Q1 FY26 financial results for the quarter ended June 30, 2025. * The quarter witnessed sequential improvement despite unseasonal rainfall and geopolitical headwinds, which impacted the seasonal portfolio (beverages and glucose). * Consolidated sales grew 1.7% (around 7% excluding the seasonal portfolio). * India business revenue grew 4.3% excluding the seasonal portfolio. * International business exhibited strong growth of 13.7% in constant currency and 12.7% in INR terms, with notable growth in MENA (10%), Sub-Saharan Africa (20%), UK (EU) (40%), United States (30%), Turkey (36%), and Bangladesh (10.2%). * Domestic Business Highlights: * HPC portfolio grew 5%. * Toothpaste portfolio delivered 7.3% growth, led by the Red franchise, gaining market share. Herbal segment outpaced non-herbal by 440 bps. * Home Care portfolio grew 10%, driven by Odonil (emerged as #1 in Air freshener with 44% volume market share, 11% growth) and Odomos (double-digit growth, gained 261 bps market share). * Skincare portfolio registered 9% growth. * Hair Oil outperformed category, gaining 214 bps market share to reach an all-time high of 19% volume market share. * Healthcare portfolio (excluding glucose) grew 9%, backed by Chyawanprash (28% growth, 111 bps market share gain) and Honey (11% growth, 46 bps market share gain). Glucose declined ~30% due to unseasonal rain but gained 118 bps market share. * Digestives portfolio: Hajmola franchise reported 9% growth, with variants contributing around 50%. Pudin Hara grew 7%. * OTC and Ethicals: Honitus registered 46% growth. Health Juices grew 18%. * J&N (Juices & Nectars) category was impacted by rains; however, 'Real Activ' franchise grew 20%. New coconut water in aseptic pet format garnered 25% of the fast-growing market. Gained 207 bps market share in nectars and 141 bps in 100% juices. * Profitability: Operating profit and PAT grew ahead of the topline, mitigating ~7% inflation through price increases (3-4%) and saving initiatives. Operating margins were maintained. Gross margins were impacted by higher BTL schemes (netting off from topline) due to competitive intensity. * Management Outlook (Mr. Mohit Malhotra, CEO): * Optimistic about sequential demand recovery due to softening food inflation, favorable monsoon, sustained rural momentum, and urban recovery. * Expects double-digit growth for Q2 FY26, leveraging a low base from last year's inventory correction. Beverage business may see low single-digit growth, while other verticals aim for double-digit growth. * Full-year guidance is for high single-digit growth. * Overall advertising and promotion expenditure increased by around 5%, with redirection from ATL to BTL. * Operating margin is targeted to improve significantly by the year-end. * Strategic focus includes: * Doubling down on core brands (Rs. 700 crore+), including Oral Care (Dabur Red, Dabur Amla), Home Care, and Skincare. * Identifying four key Healthcare brands for scaling: Pudin Hara, Health Juices, Hajmola, and Shilajit, aiming to scale them to around Rs. 100 crore each (Hajmola to Rs. 550 crore). * Improving GTM (Go-to-Market) ROI. * Continuously scouting for M&A targets, focusing on wellness foods/health, premium, and margin-accretive brands that fortify existing portfolios. * Volume growth was low single digit (~-1% reported), with price increase of 3%; net realization was -1.8% in India. Excluding the seasonal portfolio, volume growth was 3% to 3.5%. * Inventory levels are optimal at around 21-22 days.
What to do with a filing like this
Dabur India Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dabur India Limited. Read the original for the full detail.